Calcitonin-Rotexmedica

Calcitonin-Rotexmedica may be available in the countries listed below.

Ingredient matches for Calcitonin-Rotexmedica

Calcitonin

Calcitonin is reported as an ingredient of Calcitonin-Rotexmedica in the following countries:

• Germany

International Drug Name Search

Zepilen

Zepilen may be available in the countries listed below.

Ingredient matches for Zepilen

Cefazolin

Cefazolin sodium salt (a derivative of Cefazolin) is reported as an ingredient of Zepilen in the following countries:

• Croatia (Hrvatska)


• Estonia


• Lithuania

International Drug Name Search

Ketomicol

Ketomicol may be available in the countries listed below.

Ingredient matches for Ketomicol

Ketoconazole

Ketoconazole is reported as an ingredient of Ketomicol in the following countries:

• Brazil


• Peru

International Drug Name Search

Naproxen Copyfarm

Naproxen Copyfarm may be available in the countries listed below.

Ingredient matches for Naproxen Copyfarm

Naproxen

Naproxen is reported as an ingredient of Naproxen Copyfarm in the following countries:

• Sweden

International Drug Name Search

Dompenyl

Dompenyl may be available in the countries listed below.

Ingredient matches for Dompenyl

Domperidone

Domperidone is reported as an ingredient of Dompenyl in the following countries:

• Philippines

International Drug Name Search

Phenyl Aminosalicylate

Phenyl Aminosalicylate may be available in the countries listed below.

Ingredient matches for Phenyl Aminosalicylate

Fenamisal

Phenyl Aminosalicylate (BAN, USAN) is also known as Fenamisal (Rec.INN)

International Drug Name Search

Glossary

BAN	British Approved Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Didrokit

Didrokit may be available in the countries listed below.

Ingredient matches for Didrokit

Calcium Carbonate

Calcium Carbonate is reported as an ingredient of Didrokit in the following countries:

• Netherlands

Etidronic Acid

Etidronic Acid disodium salt (a derivative of Etidronic Acid) is reported as an ingredient of Didrokit in the following countries:

• Netherlands

International Drug Name Search

Olanzapine Extended-Release

Pronunciation: oh-LAN-za-peen
Generic Name: Olanzapine
Brand Name: Zyprexa Relprevv

Overdose-like side effects (eg, severe drowsiness, coma, confusion, mental changes), uncontrolled muscle movements, stiff or shaky muscles, trouble talking, joint pain, decreased coordination, aggression, dizziness, weakness, high blood pressure, and seizures have occurred in some patients after injection with Olanzapine Extended-Release. In most cases, the reaction occurred within 1 to 3 hours after the injection. You will need to be monitored by a health care professional for at least 3 hours after you receive Olanzapine Extended-Release. However, these symptoms may develop more than 3 hours after you receive a dose of Olanzapine Extended-Release. Tell your doctor right away if you develop any of these symptoms. Discuss any questions or concerns with your doctor.

Olanzapine Extended-Release is an antipsychotic. It may increase the risk of death when used to treat mental problems caused by dementia in elderly patients. Most of the deaths were linked to heart problems or infection. Olanzapine Extended-Release is not approved to treat mental problems caused by dementia.

Olanzapine Extended-Release is used for:

Treating schizophrenia. It may also be used for other conditions as determined by your doctor.

Olanzapine Extended-Release is an atypical antipsychotic. Exactly how it works is not known. It is thought to affect certain substances in the brain.

Do NOT use Olanzapine Extended-Release if:

• you are allergic to any ingredient in Olanzapine Extended-Release

Contact your doctor or health care provider right away if any of these apply to you.

Video: Treatment for Depression

Treatments for depression are getting better everyday and there are things you can start doing right away.

Before using Olanzapine Extended-Release:

Some medical conditions may interact with Olanzapine Extended-Release. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of seizures, heart problems (eg, fast, slow, or irregular heartbeat; heart failure), an abnormal electrocardiogram (ECG), a heart attack, a stroke or "mini-stroke," blood vessel problems, high blood cholesterol levels, high or low blood pressure, or low white blood cell levels


• if you have a history of liver problems, stomach or bowel problems (eg, decreased muscle movement), enlarged prostate, narrow-angle glaucoma, neuroleptic malignant syndrome (NMS), aspiration pneumonia, or suicidal thoughts or attempts


• if you have Alzheimer disease, bowel blockage, dementia, or trouble swallowing


• if you have diabetes or are very overweight, or if a family member has had diabetes


• if you have had high blood prolactin levels or a history of certain types of cancer (eg, breast, pancreas, pituitary), or if you are at risk of breast cancer


• if you are dehydrated or have low blood volume, drink alcohol, smoke, or will be exposed to high temperatures


• if you have never taken olanzapine by mouth

Some MEDICINES MAY INTERACT with Olanzapine Extended-Release. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Tramadol because the risk of seizures may be increased


• Alpha-blockers (eg, doxazosin), diazepam, or medicine for high blood pressure because the risk of low blood pressure and fainting may be increased


• Anticholinergics (eg, scopolamine), benzodiazepines (eg, lorazepam), or fluvoxamine because they may increase the risk of Olanzapine Extended-Release's side effects


• Carbamazepine, HIV protease inhibitors (eg, ritonavir), omeprazole, or rifampin because they may decrease Olanzapine Extended-Release's effectiveness


• Dopamine receptor agonists (eg, pramipexole) or levodopa because their effectiveness may be decreased by Olanzapine Extended-Release

This may not be a complete list of all interactions that may occur. Ask your health care provider if Olanzapine Extended-Release may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Olanzapine Extended-Release:

Use Olanzapine Extended-Release as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Olanzapine Extended-Release comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Olanzapine Extended-Release refilled.


• Olanzapine Extended-Release is usually given as an injection at your doctor's office, hospital, or clinic.


• Do not use Olanzapine Extended-Release if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.


• If you miss a dose of Olanzapine Extended-Release, contact your doctor right away.

Ask your health care provider any questions you may have about how to use Olanzapine Extended-Release.

Important safety information:

• Olanzapine Extended-Release may cause dizziness or drowsiness. Use Olanzapine Extended-Release with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Do not drink alcohol while you are using Olanzapine Extended-Release.


• Talk with your doctor before you use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Olanzapine Extended-Release; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.


• Olanzapine Extended-Release may cause dizziness, lightheadedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects. Tell your doctor or other health care provider if these effects occur.


• Do not become overheated or dehydrated in hot weather or while you are being active; heatstroke may occur.


• If vomiting or diarrhea occurs, you will need to take care not to become dehydrated. Contact your doctor for instructions. Contact your doctor right away if you think you may be dehydrated.


• Olanzapine Extended-Release may raise your blood sugar. High blood sugar may make you feel confused, drowsy, or thirsty. It can also make you flush, breathe faster, or have a fruit-like breath odor. If these symptoms occur, tell your doctor right away.


• Olanzapine Extended-Release may lower the ability of your body to fight infection. Avoid contact with people who have colds or infections. Tell your doctor if you notice signs of infection like fever, sore throat, rash, or chills.


• NMS is a possibly fatal syndrome that can be caused by Olanzapine Extended-Release. Symptoms may include fever; stiff muscles; confusion; abnormal thinking; fast or irregular heartbeat; and sweating. Contact your doctor at once if you have any of these symptoms.


• Some patients who take Olanzapine Extended-Release may develop muscle movements that they cannot control. This is more likely to happen in elderly patients, especially women. The chance that this will happen or that it will become permanent is greater in those who take Olanzapine Extended-Release in higher doses or for a long time. Muscle problems may also occur after short-term treatment with low doses. Tell your doctor at once if you have muscle problems with your arms; legs; or your tongue, face, mouth, or jaw (eg, chewing movements, mouth puckering, puffing of cheeks, tongue sticking out) while taking Olanzapine Extended-Release.


• Some patients have experienced weight gain while using Olanzapine Extended-Release. You may need to have regular weight checks while you use Olanzapine Extended-Release.


• Lab tests, including fasting blood glucose, cholesterol, complete blood cell counts, and liver function, may be performed while you use Olanzapine Extended-Release. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Use Olanzapine Extended-Release with caution in the ELDERLY; they may be more sensitive to its effects.


• Caution is advised when using Olanzapine Extended-Release in CHILDREN; they may be more sensitive to its effects, especially drowsiness, increased cholesterol and lipid levels, increased levels of prolactin (a hormone), and weight gain. Children may need regular weight checks while they take Olanzapine Extended-Release.


• Olanzapine Extended-Release should be used with extreme caution in CHILDREN younger than 18 years old; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Olanzapine Extended-Release while you are pregnant. Using Olanzapine Extended-Release during the third trimester may result in uncontrolled muscle movements or withdrawal symptoms in the newborn. Discuss any questions or concerns with your doctor. Olanzapine Extended-Release is found in breast milk. Do not breast-feed while using Olanzapine Extended-Release.

Possible side effects of Olanzapine Extended-Release:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Back pain; constipation; cough; diarrhea; dizziness; drowsiness; dry mouth; headache; increased appetite; lightheadedness; nausea; pain, redness, or swelling at the injection site; sore throat; stuffy nose; tiredness; vomiting; weight gain.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); abnormal thoughts; chest pain; confusion; decreased urination; disorientation; fainting; fast, slow, or irregular heartbeat; fever, chills, or persistent sore throat; increased saliva production or drooling; increased sweating; memory loss; menstrual changes; muscle pain, weakness, or stiffness; new or worsening mental or mood changes (eg, agitation, depression, hallucinations); one-sided weakness; seizures; severe or prolonged drowsiness, dizziness, or headache; shortness of breath; suicidal thoughts or actions; swelling of the hands, legs, or feet; symptoms of high blood sugar (eg, increased thirst, hunger, or urination; unusual weakness); symptoms of high prolactin levels (eg, enlarged breast size, decreased sexual ability, missed menstrual period, nipple discharge); tremor; trouble concentrating, speaking, or swallowing; trouble sitting still; trouble walking or standing; uncontrolled muscle movements (eg, arm or leg movements, twitching of the face or tongue, jerking or twisting); unusual bruising; vision changes; yellowing of the skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Olanzapine Extended-Release side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include abnormal thinking; aggression; agitation; chest pain; coma; confusion; difficult or slurred speech; fainting; fast or irregular heartbeat; fever; mental or mood changes; seizure; severe drowsiness, dizziness, or weakness; severe or persistent headache; slow or shallow breathing; stiff muscles; sweating; trouble walking; uncontrolled muscle movements.

Proper storage of Olanzapine Extended-Release:

Olanzapine Extended-Release is usually handled and stored by a health care provider. If you are using Olanzapine Extended-Release at home, store Olanzapine Extended-Release as directed by your pharmacist or health care provider. Keep Olanzapine Extended-Release out of the reach of children and away from pets.

General information:

• If you have any questions about Olanzapine Extended-Release, please talk with your doctor, pharmacist, or other health care provider.


• Olanzapine Extended-Release is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Olanzapine Extended-Release. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Olanzapine Extended-Release resources

• Olanzapine Extended-Release Side Effects (in more detail)
• Olanzapine Extended-Release Use in Pregnancy & Breastfeeding
• Drug Images
• Olanzapine Extended-Release Drug Interactions
• Olanzapine Extended-Release Support Group
• 90 Reviews for Olanzapine Extended-Release - Add your own review/rating

Compare Olanzapine Extended-Release with other medications

• Agitation
• Anorexia
• Asperger Syndrome
• Bipolar Disorder
• Body Dysmorphic Disorder
• Borderline Personality Disorder
• Depression
• Insomnia
• Obsessive Compulsive Disorder
• Paranoid Disorder
• Schizoaffective Disorder
• Schizophrenia
• Tourette's Syndrome

Vitamin D3-Hevert

Vitamin D3-Hevert may be available in the countries listed below.

Ingredient matches for Vitamin D3-Hevert

Colecalciferol

Colecalciferol is reported as an ingredient of Vitamin D3-Hevert in the following countries:

• Germany

International Drug Name Search

Epirubicin Mylan

Epirubicin Mylan may be available in the countries listed below.

Ingredient matches for Epirubicin Mylan

Epirubicin

Epirubicin hydrochloride (a derivative of Epirubicin) is reported as an ingredient of Epirubicin Mylan in the following countries:

• Slovakia

International Drug Name Search